The Feasibility of Patient-Specific Circulating Tumor DNA Monitoring throughout Multi-Modality Therapy for Locally Advanced Esophageal and Rectal Cancer: A Potential Biomarker for Early Detection of Subclinical Disease
As non-operative management (NOM) of esophageal and rectal cancer is becoming more prevalent, blood-biomarkers such as circulating tumor DNA (ctDNA) may provide clinical information in addition to endoscopy and imaging to aid in treatment decisions following chemotherapy and radiation therapy. In th...
Main Authors: | Christopher Boniface, Christopher Deig, Carol Halsey, Taylor Kelley, Michael B. Heskett, Charles R. Thomas, Paul T. Spellman, Nima Nabavizadeh |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/11/1/73 |
Similar Items
-
Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges
by: Ander Saenz-Antoñanzas, et al.
Published: (2019-07-01) -
Required Evidence for Clinical Applications of Liquid Biopsy Using Especially CTCs in Lung Cancer
by: Menno Tamminga, et al.
Published: (2020-05-01) -
Monitoring of Early Changes of Circulating Tumor DNA in the Plasma of Rectal Cancer Patients Receiving Neoadjuvant Concomitant Chemoradiotherapy: Evaluation for Prognosis and Prediction of Therapeutic Response
by: Filip Pazdirek, et al.
Published: (2020-07-01) -
Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma
by: Suman Verma, et al.
Published: (2020-10-01) -
Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients—The Importance of Tissue/Plasma Discordant Cases
by: Vincenzo Formica, et al.
Published: (2021-12-01)